---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-132874"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T10:44:20.959389+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035

## Summary
- Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.
- Effective date of any FDA approval for Fresenius Kabi's ANDA cannot be earlier than September 18, 2035 (patent expiration).
- Ruling follows partial summary judgment for infringement in May 2024 and four-day bench trial in June 2024.
- Heron will submit proposed final judgment by December 9, 2024.
- This protects CINVANTI revenue from generic competition until patents expire in 2035.

## SEC filing metadata
- accession: 0000950170-24-132874
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017024132874/0000950170-24-132874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017024132874/hrtx-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-132874
- JSON: https://secwatch.observer/filing/0000950170-24-132874.json
- Plain text: https://secwatch.observer/filing/0000950170-24-132874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.